Eileen P. Morgan

Array ( [id] => 20656553 [patent_doc_number] => 20260108587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-04-23 [patent_title] => PHARMACEUTICAL FORMULATIONS [patent_app_type] => utility [patent_app_number] => 19/423120 [patent_app_country] => US [patent_app_date] => 2025-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20447 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19423120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20650460 [patent_doc_number] => 20260102471 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-04-16 [patent_title] => PHARMACEUTICAL FORMULATIONS [patent_app_type] => utility [patent_app_number] => 19/419518 [patent_app_country] => US [patent_app_date] => 2025-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19419518 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20651496 [patent_doc_number] => 20260103509 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-04-16 [patent_title] => PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER [patent_app_type] => utility [patent_app_number] => 19/412419 [patent_app_country] => US [patent_app_date] => 2025-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17946 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19412419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20510014 [patent_doc_number] => 20260034113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-05 [patent_title] => THIADIAZOLONE DERIVATIVES, COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 19/356058 [patent_app_country] => US [patent_app_date] => 2025-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23295 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 1743 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19356058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20787446 [patent_doc_number] => 12661341 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-23 [patent_title] => Methods of treating migraine [patent_app_type] => utility [patent_app_number] => 19/331536 [patent_app_country] => US [patent_app_date] => 2025-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 11531 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19331536 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20320040 [patent_doc_number] => 20250332128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-30 [patent_title] => COMPOSITIONS AND COMPOUNDS CONTAINNG KETONE BODIES AND/OR KETONE BODY PRECURSORS AND ONE OR MORE AMINO ACIDS [patent_app_type] => utility [patent_app_number] => 19/261853 [patent_app_country] => US [patent_app_date] => 2025-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10522 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19261853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20714145 [patent_doc_number] => 12629369 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-19 [patent_title] => Pharmaceutical compositions of nilotinib [patent_app_type] => utility [patent_app_number] => 19/258578 [patent_app_country] => US [patent_app_date] => 2025-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 12682 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19258578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20729041 [patent_doc_number] => 12636285 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-26 [patent_title] => Method for treating HIV with cabotegravir and rilpivirine [patent_app_type] => utility [patent_app_number] => 19/227593 [patent_app_country] => US [patent_app_date] => 2025-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 12333 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 201 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19227593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20729042 [patent_doc_number] => 12636286 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-26 [patent_title] => Method for treating HIV with cabotegravir and rilpivirine [patent_app_type] => utility [patent_app_number] => 19/227609 [patent_app_country] => US [patent_app_date] => 2025-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 12358 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 223 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19227609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20192154 [patent_doc_number] => 20250268864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-28 [patent_title] => PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME [patent_app_type] => utility [patent_app_number] => 19/206909 [patent_app_country] => US [patent_app_date] => 2025-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17316 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 274 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19206909 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20479340 [patent_doc_number] => 12527803 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-20 [patent_title] => Testosterone dodecanoate compositions and methods [patent_app_type] => utility [patent_app_number] => 19/059754 [patent_app_country] => US [patent_app_date] => 2025-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 17442 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19059754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20466536 [patent_doc_number] => 12522568 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-13 [patent_title] => Amino acid compositions [patent_app_type] => utility [patent_app_number] => 19/030399 [patent_app_country] => US [patent_app_date] => 2025-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8264 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19030399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20357278 [patent_doc_number] => 12473261 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-18 [patent_title] => Amino acid compositions [patent_app_type] => utility [patent_app_number] => 19/030439 [patent_app_country] => US [patent_app_date] => 2025-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8277 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19030439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20014316 [patent_doc_number] => 20250152538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-15 [patent_title] => METHOD FOR TREATING A DISORDER [patent_app_type] => utility [patent_app_number] => 19/021386 [patent_app_country] => US [patent_app_date] => 2025-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19021386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19938833 [patent_doc_number] => 12310946 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-27 [patent_title] => Pharmaceutical composition for oral administration of edaravone and method of administering same [patent_app_type] => utility [patent_app_number] => 18/932667 [patent_app_country] => US [patent_app_date] => 2024-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 4 [patent_no_of_words] => 17302 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 250 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18932667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19947058 [patent_doc_number] => 12318396 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-06-03 [patent_title] => Oral (17-b)-3-oxoandrost-4-en-17-yl tridecanoate therapy [patent_app_type] => utility [patent_app_number] => 18/924252 [patent_app_country] => US [patent_app_date] => 2024-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 22893 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18924252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19707740 [patent_doc_number] => 20250017882 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-16 [patent_title] => GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE [patent_app_type] => utility [patent_app_number] => 18/898132 [patent_app_country] => US [patent_app_date] => 2024-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27560 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18898132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19845161 [patent_doc_number] => 20250090512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => Dosage Regimen [patent_app_type] => utility [patent_app_number] => 18/790828 [patent_app_country] => US [patent_app_date] => 2024-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 82635 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 266 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18790828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19637396 [patent_doc_number] => 12167992 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-17 [patent_title] => Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state [patent_app_type] => utility [patent_app_number] => 18/758358 [patent_app_country] => US [patent_app_date] => 2024-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 17 [patent_no_of_words] => 27619 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18758358 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19637395 [patent_doc_number] => 12167991 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-17 [patent_title] => Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state [patent_app_type] => utility [patent_app_number] => 18/758344 [patent_app_country] => US [patent_app_date] => 2024-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 17 [patent_no_of_words] => 27570 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18758344 [rel_patent_id] =>[rel_patent_doc_number] =>)